Trials / Completed
CompletedNCT01356173
Evaluating the Safety and Tolerability of GDC-0349 in Patients With Locally Advanced or Metastatic Solid Tumors or Non Hodgkin's Lymphoma
An Open-Label, Phase I, Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0349 in Patients With Locally Advanced or Metastatic Solid Tumors or Non Hodgkin's Lymphoma
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 10 (actual)
- Sponsor
- Genentech, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is an open-label, multicenter, Phase I, dose-escalation study to assess the safety, tolerability, and pharmacokinetic (PK) of GDC-0349 administered once daily (QD), orally (PO).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | GDC-0349 | Oral escalating dose |
Timeline
- Start date
- 2011-06-01
- Primary completion
- 2012-12-01
- Completion
- 2012-12-01
- First posted
- 2011-05-19
- Last updated
- 2016-11-02
Locations
2 sites across 2 countries: United States, Canada
Source: ClinicalTrials.gov record NCT01356173. Inclusion in this directory is not an endorsement.